Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Investing Activities: 2015-2024

Historic Cash from Investing Activities for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $125.6 million.

  • Intellia Therapeutics' Cash from Investing Activities rose 90.39% to -$741,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $352.1 million, marking a year-over-year increase of 1665.52%. This contributed to the annual value of $125.6 million for FY2024, which is 500.57% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Cash from Investing Activities of $125.6 million as of FY2024, which was up 500.57% from -$31.3 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Cash from Investing Activities registered a high of $160.3 million during FY2022, and its lowest value of -$550.8 million during FY2021.
  • Its 3-year average for Cash from Investing Activities is $84.8 million, with a median of $125.6 million in 2024.
  • As far as peak fluctuations go, Intellia Therapeutics' Cash from Investing Activities slumped by 951.95% in 2020, and later spiked by 500.57% in 2024.
  • Intellia Therapeutics' Cash from Investing Activities (Yearly) stood at -$214.5 million in 2020, then crashed by 156.79% to -$550.8 million in 2021, then surged by 129.11% to $160.3 million in 2022, then slumped by 119.55% to -$31.3 million in 2023, then spiked by 500.57% to $125.6 million in 2024.